research Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
Sintilimab treatment caused hair loss but led to complete tumor remission.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Transient chemotherapy-induced alopecia after intralesional 5-fluorouracil treatment of keloids
Temporary hair loss can occur after 5-fluorouracil treatment for keloids.
research Targeted delivery of extracellular vesicles: the mechanisms, techniques and therapeutic applications
Engineered extracellular vesicles show promise for targeted therapy but need more research for clinical use.
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research PEG-Immobilized Keratin for Protein Drug Sequestration and pH-Mediated Delivery
PEG and keratin scaffolds can effectively deliver protein drugs by controlling release based on pH levels.
research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.
Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research A new way to restore tumour suppressor function
New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
research Hyperammonemia with Valproic Acid: Colonic Ischemia Associated with “Triptan” Use Visual Side Effects with Pegylated Interferon: Alopecia Areata with Infliximab: Adverse Effects Seen with Medications Used for Irritable Bowel Syndrome
Certain medications can cause serious side effects, so it's important to report them.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Tratamiento con tofacitinib en adolescentes con alopecia areata
Tofacitinib treatment is used for teenagers with alopecia areata.
research Tumor Angiogenesis and Anti-angiogenic Therapy
Anti-angiogenic therapy can help treat cancer but may cause resistance and side effects, so alternative methods are being explored.
research Nanoparticle systems reduce systemic toxicity in cancer treatment
Nanoparticle systems make cancer treatment less toxic.
research JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
research Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis against Kidney Injury
Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
research The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Transdermal film-loaded finasteride microplates to enhance drug skin permeation: Two-step optimization study
Optimized film improves finasteride skin absorption and treatment efficiency.
research Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time
Advanced imaging methods have improved understanding of cancer cell interactions and treatment strategies.
research The successful treatment of nephrogenic fibrosing dermopathy (NFD) with mycophenolate mofetil (MMF)
Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
research miR-150 regulates endothelial progenitor cell differentiation via Akt and promotes thrombus resolution
miR-150 helps blood vessel cells develop and speeds up blood clot healing.
research BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
research In reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.